Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease

Bone

Volumn 61, Issue , 2014, Pages 208-216

  Seeley, Erin H ^a   Wilson, Kevin J ^b,c   Yankeelov, Thomas E ^a,b,c,d   Johnson, Rachelle W ^a,c   Gore, John C ^b,c,d   Caprioli, Richard M ^a,c,e   Matrisian, Lynn M ^a   Sterling, Julie A ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone; Image co registration; MALDI; Metastases; MRI

Indexed keywords

BONE; IMAGE CO-REGISTRATION; MALDI; METASTASES; MRI;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MULTIMODAL IMAGING; NEOPLASM METASTASIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84894042246     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.01.017     Document Type: Article

References (33)

1. Sterling J.A., Edwards J.R., Martin T.J., Mundy G.R. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011, 48:6-15.
2. Kakonen S.M., Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834-839.
3. Anderson A.W., Xie J., Pizzonia J., Bronen R.A., Spencer D.D., Gore J.C. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 2000, 18:689-695.
4. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008, 5:220-233.
5. Chaurand P., Schwartz S.A., Caprioli R.M. Profiling and imaging proteins in tissue sections by MS. Anal Chem 2004, 76:86A-93A.
6. Stoeckli M., Chaurand P., Hallahan D.E., Caprioli R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001, 7:493-496.
7. Chaurand P., Norris J.L., Cornett D.S., Mobley J.A., Caprioli R.M. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 2006, 5:2889-2900.
8. Schafer R. Ultraflextreme: redefining MALDI mass spectrometry performance 2009, 14-15. LCGC, North Am.
9. Schwamborn K., Krieg R.C., Reska M., Jakse G., Knuechel R., Wellmann A. Identifying prostate carcinoma by MALDI-imaging. Int J Mol Med 2007, 20:155-159.
10. Reyzer M.L., Caldwell R.L., Dugger T.C., Forbes J.T., Ritter C.A., Guix M., et al. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 2004, 64:9093-9100.
11. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
12. Caldwell R.L., Gonzalez A., Oppenheimer S.R., Schwartz H.S., Caprioli R.M. Molecular assessment of the tumor protein microenvironment using imaging mass spectrometry. Cancer Genomics Proteomics 2006, 3:279-288.
13. van der Merwe D.-E., Oikonomopoulou K., Marshall J., Diamandis Eleftherios P. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 2007, 96:23-50.
14. Corbin B.D., Seeley E.H., Raab A., Feldmann J., Miller M.R., Torres V.J., et al. Metal chelation and inhibition of bacterial growth in tissue abscesses. Science 2008, 319:962-965.
15. Stoeckli M., Knochenmuss R., McCombie G., Mueller D., Rohner T., Staab D., et al. MALDI MS imaging of amyloid. Methods Enzymol 2006, 412:94-106.
16. Drexler D.M., Garrett T.J., Cantone J.L., Diters R.W., Mitroka J.G., Prieto Conaway M.C., et al. Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods 2007, 55:279-288.
17. Khatib-Shahidi S., Andersson M., Herman J.L., Gillespie T.A., Caprioli R.M. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal Chem 2006, 78:6448-6456.
18. Stoeckli M., Staab D., Schweitzer A. Compound and metabolite distribution measured by MALDI mass spectrometric imaging in whole-body tissue sections. Int J Mass Spectrom 2007, 260:195-202.
19. Andersson M., Groseclose M.R., Deutch A.Y., Caprioli R.M. Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Methods 2008, 5:101-108.
20. Cornett D.S., Mobley J.A., Dias E.C., Andersson M., Arteaga C.L., Sanders M.E., et al. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 2006, 5:1975-1983.
21. Sinha T.K., Khatib-Shahidi S., Yankeelov T.E., Mapara K., Ehtesham M., Cornett D.S., et al. Integrating spatially resolved three-dimensional MALDI IMS with in vivo magnetic resonance imaging. Nat Met 2008, 5:57-59.
22. Attia A.S., Schroeder K.A., Seeley E.H., Wilson K.J., Hammer N.D., Colvin D.C., et al. Monitoring the inflammatory response to infection through the integration of MALDI IMS and MRI. Cell Host Microbe 2012, 11:664-673.
23. Sterling J.A., Oyajobi B.O., Grubbs B., Padalecki S.S., Munoz S.A., Gupta A., et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006, 66:7548-7553.
24. Johnson R.W., Nguyen M.P., Padalecki S.S., Grubbs B.G., Merkel A.R., Oyajobi B.O., et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 2011, 71:822-831.
25. Andersson M., Groseclose M.R., Deutch A.Y., Caprioli R.M. Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Methods 2008, 5:101-108.
26. Norris J.L., Cornett D.S., Mobley J.A., Andersson M., Seeley E.H., Chaurand P., et al. Processing MALDI mass spectra to improve mass spectral direct tissue analysis. Int J Mass Spectrom 2007, 260:212-221.
27. Herring K.D. Identification of protein markers of drug-induced nephrotoxicity by MALDI MS. In vivo Discovery of Ubiquitin-t 2009, 110. Vanderbilt University, Nashville, TN. Department of Biochemistry (Ed.).
28. Xie L., Xu B.J., Gorska A.E., Shyr Y., Schwartz S.A., Cheng N., et al. Genomic and proteomic analysis of mammary tumors arising in transgenic mice. J Proteome Res 2005, 4:2088-2098.
29. Schwartz S.A., Weil R.J., Thompson R.C., Shyr Y., Moore J.H., Toms S.A., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65:7674-7681.
30. Filipek A., Michowski W., Kuznicki J. Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul 2008, 48:225-239.
31. Ghavami S., Chitayat S., Hashemi M., Eshraghi M., Chazin W.J., Halayko A.J., et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol 2009, 625:73-83.
32. Morgan T.M., Seeley E.H., Fadare O., Caprioli R.M., Clark P.E. Imaging the clear cell renal cell carcinoma proteome. J Urol 2013, 189:1097-1103.
33. Hardesty W.M., Kelley M.C., Mi D., Low R.L., Caprioli R.M. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011, 74:1002-1014.